Self-complementary adeno-associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain

Molecular Therapy

Volumn 8, Issue 6, 2003, Pages 911-917

  Fu, Haiyan ^a   Muenzer, Joseph ^a   Samulski, Richard J ^a   Breese, George ^a   Sifford, Jerillyn ^a   Zeng, Xinhua ^a   McCarty, Douglas M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; MANNITOL; PARVOVIRUS VECTOR; SINGLE STRANDED DNA;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM; CONTROLLED STUDY; DRUG DISTRIBUTION; GENE EXPRESSION; GENE LOCATION; GENE TRANSFER; GENETIC TRANSDUCTION; GLIA CELL; INFUSION; LIVER; LIVER CELL; LYSOSOME STORAGE DISEASE; MOUSE; NERVE CELL; NONHUMAN; OLFACTORY CORTEX; PURKINJE CELL; REPORTER GENE; SEROTYPE; SPINAL CORD; TISSUE LEVEL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; ANIMALIA; PARVOVIRUS;

EID: 0347286956     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.08.021     Document Type: Article

References (27)

1. Berns, K. I., and Linden, R. M. (1995). The cryptic life style of adeno-associated virus. Bioessays 17: 237-245.
2. Samulski, R. J., Chang, L. S., and Shenk, T. (1989). Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63: 3822-3828.
3. McCown, T. J., Xiao, X., Li, J., Breese, G. R., and Samulski, R. J. (1996). Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713: 99-107.
4. Klein, R. L., et al. (1998). Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150: 183-194.
5. Klein, R. L., Mandel, R. J., and Muzyczka, N. (2000). Adeno-associated virus vector-mediated gene transfer to somatic cells in the central nervous system. Adv. Virus Res. 55: 507-528.
6. Bankiewicz, K. S., et al. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys: in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164: 2-14.
7. Bjorklund, A, F., Kirik, D. F., Rosenblad, C. F., Georgievska, B. F., Lundberg, C. F., and Mandel, R. J. (2000). Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigro-striatal system in the rat Parkinson model. Brain Res. 886: 82-98.
8. During, M. J. F., et al. (1998). In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5: 820-827.
9. Nakai, H., Storm, T. A., and Kay, M. A. (2000). Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74: 9451-63.
10. McCarty, D. M., Monahan, P. E., and Samulski, R. J. (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8: 1248-1254.
11. Gloor, S. M. F., Wachtel, M. F., Bolliger, M, F. F., Ishihara, H. F., Landmann, R. F., and Frei, K. (2001). Molecular and cellular permeability control at the blood-brain barrier. Brain Res. Brain Res. Rev. 36: 258-264.
12. Rapoport, S. I. (2001). Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin. Invest. Drugs 10: 1809-1818.
13. Li, H. F., Sun, H. F., and Qian, Z. M. (2002). The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol. Sci. 23: 206-209.
14. Neuwelt, E. A. F., et al. (1979). Osmotic blood-brain barrier disruption: a new means of increasing chemotherapeutic agent delivery. Trans. Am. Neurol. Assoc. 104: 256-260.
15. Wu, D. F., Song, B. W. F., Vinters, H. V. F., and Pardridge, W. M. (2002). Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Target. 10: 239-245.
16. Kreuter, J. F., et al. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10: 317-325.
17. Kreuter, J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv. Drug Delivery Rev. 47: 65-81.
18. Koizumi, M. F., Nakanishi, Y. F., Sato, H. F., Morinaga, Y. F., Ido, T. F., and Kimura, S. (2002). Uptake across the blood-brain barrier and tissue distribution of enterostatin after peripheral administration in rats. Physiol. Behav. 77: 5.
19. Nilaver, G. F., et al. (1995). Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc. Natl. Acad. Sci. USA 92: 9829-9833.
20. Wilson, A. J. F., Evill, C. A. F., and Sage, M. R. (1991). Effects of nonionic contrast media on the blood-brain barrier. Osmolality versus chemotoxicity. Invest. Radiol. 26: 1091-1094.
21. Zolotukhin, S., et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6: 973-985.
22. Rabinowitz, J., Monahan, P., and Samulski, R. J. (2001). In vitro properties of AAV serotypes 1-5. Mol. Ther. 3: S189.
23. Fu, H. F., Samulski, R. J. F., McCown, T. J. F., Picornell, Y. J. F., Fletcher, D. F., and Muenzer, J. (2002). Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol. Ther. 5: 42-49.
24. Franklin, K. B. J., and Paxinos, G. (1997). Figures. In The Mouse Brain in Stereotaxic Coordinates (K. B. J. Franklin and G. Paxinos, Eds.), pp. 1-93. Academic Press, San Diego, CA.
25. Breese, G. R., Chase, T. N., and Kopin, I. J. (1969). Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain. J. Pharmacol. Exp. Ther. 165: 9-13.
26. Breese, G. R., and Traylor, T. D. (1972). Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine. Br. J. Pharmacol. 44: 210-222.
27. Ikeda, M. F., Bhattacharjee, A. K. F., Kondoh, T. F., Nagashima, T. F., and Tamaki, N. (2002). Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem. Biophys. Res. Commun. 291: 669-674.